Documento SER de consenso sobre el uso de terapias biológicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psoriásica
Tóm tắt
Từ khóa
Tài liệu tham khảo
Van der Linden, 1984, Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria, Arthritis Rheum., 27, 361, 10.1002/art.1780270401
Braun J, Kingsley G, Van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol. 2000; 27:2185-92.
Taylor, 2006, Classification criteria for psoriatic arthritis: development of new criteria from a large international study, Arthritis Rheum., 54, 2665, 10.1002/art.21972
Dougados, 1991, The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy, Arthritis Rheum., 34, 1218, 10.1002/art.1780341003
Amor, 1990, Criteria of the classification of spondylarthropathies, Rev Rhum Mal Osteoartic., 57, 85
Braun, 2002, Mortality, course of disease and prognosis of patients with ankylosing spondylitis, Clin Exp Rheumatol., 20, S16
Rudwaleit, 2005, The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?, Arthritis Rheum., 52, 1000, 10.1002/art.20990
Sieper, 2009, New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS), Ann Rheum Dis., 68, 784, 10.1136/ard.2008.101501
Rudwaleit, 2009, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal, Ann Rheum Dis., 68, 770, 10.1136/ard.2009.108217
Rudwaleit, 2009, New ASAS classification criteria for peripheral spondyloarthritis, Ann Rheum Dis.
Rudwaleit, 2009, The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort, Arthritis Rheum., 60, 717, 10.1002/art.24483
Braun, 1998, Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors, Arthritis Rheum., 41, 58, 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G
Gran, 1993, The epidemiology of ankylosing spondylitis, Semin Arthritis Rheum., 22, 319, 10.1016/S0049-0172(05)80011-3
Munoz-Fernandez, 2010, The incidence of early spondyloarthritis: results from the pilot registry ESPIDEP, Clin Exp Rheumatol.
Muñoz Gomariz, 1994, Validación de criterios diagnósticos y de clasificación de las espondiloartropatías: Estudio multicéntrico en España, Rev Esp Reumatol., 21, 426
Rojas-Vargas, 2009, First signs and symptoms of spondyloarthritis –data from an inception cohort with a disease course of two years or less (REGISPONSER-Early), Rheumatology (Oxford)., 48, 404, 10.1093/rheumatology/ken506
Guillemin, 1990, Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors, Arthritis Rheum., 33, 1001, 10.1002/art.1780330712
Ariza-Ariza, 2009, Work disability in patients with ankylosing spondylitis, J Rheumatol., 36, 2512, 10.3899/jrheum.090481
Van der Heijde, 2010, Spondyloarthritis: state of the art and future perspectives, Ann Rheum Dis., 69, 949, 10.1136/ard.2009.119529
Grupo ESPOGUIA. Fármacos modificadores de la enfermedad. Madrid: SER; 2010.
Clegg, 1999, Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study, Arthritis Rheum., 42, 2325, 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C
Wanders, 2005, Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial, Arthritis Rheum., 52, 1756, 10.1002/art.21054
Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica: RAND; 2001.
Sociedad Española de Reumatología. Guía de práctica clínica sobre el manejo de los pacientes con espondiloartritis (ESPOGUIA) 2010.
Collantes, 2007, Documento de consenso: Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF en las espondiloartritis, incluida la artritis psoriásica, Reumatol Clin., 3, 60, 10.1016/S1699-258X(07)73645-8
CEBM CfEBM. Oxford Centre for Evidence-based Medicine -Levels of Evidence (March 2009). 2009.
Brandt, 2002, Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab, J Rheumatol., 29, 118
Braun, 2002, Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, Lancet., 359, 1187, 10.1016/S0140-6736(02)08215-6
Calin, 2004, Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis, Ann Rheum Dis., 63, 1594, 10.1136/ard.2004.020875
Heiberg, 2005, The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study, Arthritis Rheum., 52, 2506, 10.1002/art.21209
Van der Heijde, 2006, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum., 54, 2136, 10.1002/art.21913
Revicki, 2008, Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS), J Rheumatol., 35, 1346
Carmona, 2006, Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER, Arthritis Res Ther., 8, R72, 10.1186/ar1941
Venetsanopoulou, 2007, Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis, Rheumatol Int., 27, 935, 10.1007/s00296-007-0330-9
Van der Heijde, 2008, Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis, Ann Rheum Dis., 67, 1218, 10.1136/ard.2007.082529
Rudwaleit, 2009, Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion, Rheumatology (Oxford)., 48, 551, 10.1093/rheumatology/kep022
Baraliakos, 2005, Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab, Arthritis Res Ther., 7, R439, 10.1186/ar1693
Haibel, 2008, Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two, Arthritis Rheum., 58, 1981, 10.1002/art.23606
Rudwaleit, 2009, Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis, J Rheumatol., 36, 801, 10.3899/jrheum.081048
Van der Heijde, 2008, Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis, Arthritis Rheum., 58, 3063, 10.1002/art.23901
Van der Heijde, 2008, Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept, Arthritis Rheum., 58, 1324, 10.1002/art.23471
Van der Heijde, 2009, Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years, Arthritis Res Ther., 11, R127, 10.1186/ar2794
Braun, 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum., 52, 2447, 10.1002/art.21197
Fernandez-Nebro, 2005, Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists, Am J Med., 118, 552, 10.1016/j.amjmed.2005.01.028
Hatemi, 2008, Tumor necrosis factor alpha antagonists in the treatment of secondary amiloidosis, Arthritis Rheum., 58, S475
Behm, 2008, Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev., 10.1002/14651858.CD006893
Lawson, 2006, Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis, Cochrane Database Syst Rev., 3, 10.1002/14651858.CD005112.pub2
Lange, 2005, Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study, Rheumatology (Oxford)., 44, 1546, 10.1093/rheumatology/kei082
Mathieu, 2010, Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis, Joint Bone Spine., 77, 50, 10.1016/j.jbspin.2009.05.012
Brandt, 2003, Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum., 48, 1667, 10.1002/art.11017
Baraliakos, 2007, Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis, J Rheumatol., 34, 510
Brandt, 2005, Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis, Rheumatology (Oxford)., 44, 342, 10.1093/rheumatology/keh475
Galor, 2006, Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation, Ophthalmology., 113, 2317, 10.1016/j.ophtha.2006.04.038
Delaunay, 2005, Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data, J Rheumatol., 32, 2183
Van der Heijde, 2006, Etanercept 50mg once weekly is as effective as 25mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis., 65, 1572, 10.1136/ard.2006.056747
Gorman, 2002, Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha, N Engl J Med., 346, 1349, 10.1056/NEJMoa012664
Davis, 2003, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial, Arthritis Rheum., 48, 3230, 10.1002/art.11325
Meador, 2001, Is etanercept (Enbrel) effective in the treatment of reactive and undifferentiated arthritis?, Arthritis Rheum., 44, S348
Flagg, 2005, Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial, Arthritis Rheum., 53, 613, 10.1002/art.21323
Boonen, 2008, Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept, J Rheumatol., 35, 662
Baraliakos, 2005, Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept, Arthritis Rheum., 52, 1216, 10.1002/art.20977
Rudwaleit, 2005, Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept, Ann Rheum Dis., 64, 1305, 10.1136/ard.2004.032441
De Vries, 2009, Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis, Ann Rheum Dis., 68, 531, 10.1136/ard.2008.089979
Maksymowych, 2005, Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis, J Rheumatol., 32, 1911
Woo, 2007, Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept, J Rheumatol., 34, 1753
Barkham, 2010, Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis, Ann Rheum Dis., 10.1136/ard.2009.121327
Van Eijk, 2009, Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade, Ann Rheum Dis., 68, 362, 10.1136/ard.2007.086777
Sieper, 2010, Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials, Ann Rheum Dis., 69, 226, 10.1136/ard.2008.103192
Davis, 2008, Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis, Ann Rheum Dis., 67, 346, 10.1136/ard.2007.078139
Baraliakos, 2005, Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data, Arthritis Rheum., 53, 856, 10.1002/art.21588
Martin-Mola, 2010, Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis, Clin Exp Rheumatol., 28, 238
Maksymowych, 2002, Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety, J Rheumatol., 29, 959
Keeling, 2006, Prospective observational analysis of the efficacy and safety of low-dose (3mg/kg) infliximab in ankylosing spondylitis: 4-year followup, J Rheumatol., 33, 558
D’Agostino, 2002, Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound, Arthritis Rheum., 46, 840, 10.1002/art.513
Gaylis, 2003, Infliximab in the treatment of an HIV positive patient with Reiter's syndrome, J Rheumatol., 30, 407
Schafranski, 2010, Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection, Rheumatol Int., 30, 679, 10.1007/s00296-009-0965-9
Van den Bosch, 2000, Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study, Ann Rheum Dis., 59, 428, 10.1136/ard.59.6.428
Van Den Bosch, 2002, Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy, Arthritis Rheum., 46, 755, 10.1002/art.511
Braun, 2003, Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system, Arthritis Rheum., 48, 1126, 10.1002/art.10883
Barkham, 2009, Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis, Arthritis Rheum., 60, 946, 10.1002/art.24408
Marzo-Ortega, 2005, Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study, Ann Rheum Dis., 64, 1568, 10.1136/ard.2004.022582
Van der Heijde, 2006, Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial, Arthritis Rheum., 55, 569, 10.1002/art.22097
Visvanathan, 2009, Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis, Ann Rheum Dis., 68, 175, 10.1136/ard.2007.084426
Kiortsis, 2006, Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis, J Rheumatol., 33, 921
Kruithof, 2002, Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis, Ann Rheum Dis., 61, 470, 10.1136/ard.61.5.470
Guignard, 2006, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis., 65, 1631, 10.1136/ard.2006.052092
Suhler, 2005, A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes, Arch Ophthalmol., 123, 903, 10.1001/archopht.123.7.903
Sobrin, 2007, Infliximab therapy for the treatment of refractory ocular inflammatory disease, Arch Ophthalmol., 125, 895, 10.1001/archopht.125.7.895
Cobo, 2006, Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment, Med Clin (Barc)., 126, 34
Teshima, 2009, Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort, Can J Gastroenterol., 23, 348, 10.1155/2009/180840
Braun, 2005, Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis, Ann Rheum Dis., 64, 229, 10.1136/ard.2004.025130
Breban, 2008, Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment, Arthritis Rheum., 58, 88, 10.1002/art.23167
Rudwaleit, 2010, Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis, Arthritis Res Ther., 12, R43, 10.1186/ar2953
Davis, 2007, Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study, Arthritis Rheum., 57, 1050, 10.1002/art.22887
Bacquet-Deschryver, 2008, Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients, J Clin Immunol., 28, 445, 10.1007/s10875-008-9214-3
Maksymowych, 2010, Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis, J Rheumatol., 37, 385, 10.3899/jrheum.090242
Sanchez-Cano, 2007, Use of adalimumab in poststreptococcal reactive arthritis, J Clin Rheumatol., 13, 176, 10.1097/RHU.0b013e3180690c1f
Rudwaleit, 2010, Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy, Arthritis Res Ther., 12, R117, 10.1186/ar3054
Lambert, 2007, Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study, Arthritis Rheum., 56, 4005, 10.1002/art.23044
Maksymowych, 2008, Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis, J Rheumatol., 35, 2030
Rudwaleit, 2009, Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study, Ann Rheum Dis., 68, 696, 10.1136/ard.2008.092585
Van der Heijde, 2009, Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis, Arthritis Res Ther., 11, R124, 10.1186/ar2790
Inman, 2008, Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial, Arthritis Rheum., 58, 3402, 10.1002/art.23969
Braun, 2008, Golimumab significantly improves productivity in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study, Arthritis Rheum., 58
Deodhar, 2010, Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial, Arthritis Care Res (Hoboken)., 62, 1266, 10.1002/acr.20233
Van der Heijde, 2008, Head to head comparison of three enthesitis indices in the ankylosing spondilytis anti-TNF-? trial of Golimumab (GO-RAISE), Arthritis Rheum., 58, S369
Furst, 2008, Golimumab, a new human anti-TNF-alpha monoclonal antibody administered subcutaneously every 4 weeks, improves anemia & well-being in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, Arthritis Rheum., 58
Rudwaleit, 2010, New approaches to diagnosis and classification of axial and peripheral spondyloarthritis, Curr Opin Rheumatol., 22, 375, 10.1097/BOR.0b013e32833ac5cc
Van der Heijde, 2005, Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study, Arthritis Rheum., 52, 1205, 10.1002/art.20985
Jarrett, 2009, MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib, Ann Rheum Dis., 68, 1466, 10.1136/ard.2008.092213
Lukas, 2009, Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis, Ann Rheum Dis., 68, 18, 10.1136/ard.2008.094870
Van der Heijde, 2009, ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis, Ann Rheum Dis., 68, 1811, 10.1136/ard.2008.100826
Pedersen, 2010, Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors, Ann Rheum Dis., 69, 1065, 10.1136/ard.2009.111187
Garrett, 1994, A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol., 21, 2286
Stone, 2004, Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics, Arthritis Rheum., 51, 316, 10.1002/art.20414
Wanders, 2004, Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis, Arthritis Rheum., 51, 1, 10.1002/art.20075
Sieper, 2009, The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis, Ann Rheum Dis., 68, ii1, 10.1136/ard.2008.104018
Calin, 1994, A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index, J Rheumatol., 21, 2281
Anderson, 2001, Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis, Arthritis Rheum., 44, 1876, 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
Brandt, 2004, Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis, Ann Rheum Dis., 63, 1438, 10.1136/ard.2003.016717
Rudwaleit, 2004, How to diagnose axial spondyloarthritis early, Ann Rheum Dis., 63, 535, 10.1136/ard.2003.011247
Bennett, 2008, Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years, Arthritis Rheum., 58, 3413, 10.1002/art.24024
Rudwaleit, 2009, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis., 68, 777, 10.1136/ard.2009.108233
Rudwaleit, 2008, MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis, Ann Rheum Dis., 67, 1276, 10.1136/ard.2007.073098
Bennett, 2009, Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis, Arthritis Rheum., 60, 1331, 10.1002/art.24493
Rudwaleit, 2009, Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group, Ann Rheum Dis., 68, 1520, 10.1136/ard.2009.110767
Balint, 2002, Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy, Ann Rheum Dis., 61, 905, 10.1136/ard.61.10.905
D’Agostino, 2003, Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study, Arthritis Rheum., 48, 523, 10.1002/art.10812
De Miguel, 2009, Validity of enthesis ultrasound assessment in spondyloarthropathy, Ann Rheum Dis., 68, 169, 10.1136/ard.2007.084251
Naredo, 2010, Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities, J Rheumatol., 37, 2110, 10.3899/jrheum.100136
Machado, 2010, Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores, Ann Rheum Dis.
Conti, 2007, Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period, Ann Rheum Dis., 66, 1393, 10.1136/ard.2007.073569
Inman, 2010, A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis, J Rheumatol., 37, 1203, 10.3899/jrheum.091042
Jois, 2006, Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective, Rheumatology (Oxford)., 45, 1566, 10.1093/rheumatology/kel156
Abad, 2009, Eficacia de la suspensión de biológicos en la EA controlada
Torrente, 2009